FIELD OF THE INVENTION
The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
FIELD OF THE DISCLOSURE
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1.alpha.), as well as hypoxia inducible factor-2 alpha (HIF-2.alpha.). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed
TECHNICAL FIELD
Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their
TECHNICAL FIELD
Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their
FIELD OF THE INVENTION
This invention describes the use of rho GTPase function inhibitors as upregulators of Type III endothelial cell Nitric Oxide Synthase. Further, this invention describes methods that employ Rho GTPase function inhibitors to treat conditions that result from the abnormally low
FIELD OF THE INVENTION
This invention relates to the use of agents that disrupt actin cytoskeletal organization as upregulators of Type III endothelial cell Nitric Oxide Synthase. Further, this invention relates to methods that employ agents that disrupt actin cytoskeletal organization to treat
TECHNICAL FIELD
This invention relates to the treatment of respiratory, cardiac and blood disorders by delivery into the lungs of compound comprising NO.
BACKGROUND OF THE INVENTION
Inhaled NO is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia. This
TECHNICAL FIELD
This invention relates to the treatment of respiratory, cardiac and blood disorders by delivery into the lungs of compound comprising NO substitute.
BACKGROUND OF THE INVENTION
Inhaled NO is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia.
FIELD OF THE INVENTION
This invention describes the new use of HMG-CoA reductase inhibitors as upregulators of Type III endothelial cell Nitric Oxide Synthase. Further, this invention describes methods that employ HMG-CoA reductase inhibitors to treat conditions that result from the abnormally low
FIELD OF THE INVENTION
This invention relates generally to the area of diagnosis of heart disease, and specifically relates to methods of diagnosis of heart failure, cardiac ischemia, or hypoxia by detecting the level, e.g., concentration, of a non-polypeptidic cardiac marker as an indicator of
FIELD OF THE INVENTION
This invention relates generally to the area of diagnosis of heart disease, and specifically relates to methods of diagnosis of heart failure, cardiac ischemia, or hypoxia by detecting the level, e.g., concentration, of a non-polypeptidic cardiac marker as an indicator of
FIELD OF THE INVENTION
This invention relates generally to the area of diagnosis of heart disease, and specifically relates to methods of diagnosis of heart failure, cardiac ischemia, or hypoxia by detecting the level, e.g., concentration, of a non-polypeptidic cardiac marker as an indicator of
Najkompletnija baza ljekovitog bilja potpomognuta znanošću
Radi na 55 jezika
Biljni lijekovi potpomognuti znanošću
Prepoznavanje bilja slikom
Interaktivna GPS karta - označite bilje na mjestu (uskoro)
Pročitajte znanstvene publikacije povezane s vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi. * Svi podaci temelje se na objavljenim znanstvenim istraživanjima